The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-co-Reference-Cited by-同舟云学术

The first trial of CIM331, a humanized antihuman interleukin-31 receptor A antibody, in healthy volunteers and patients with atopic dermatitis to evaluate safety, tolerability and pharmacokinetics of a single dose in a randomized, double-blind, placebo-co

Published:2015-12-19 Issue:2 Volume:174 Page:296-304
ISSN:0007-0963
Container-title:British Journal of Dermatology
language:en
Short-container-title:Br J Dermatol

Author:

Nemoto O.¹,Furue M.²,Nakagawa H.³,Shiramoto M.⁴,Hanada R.⁵,Matsuki S.⁶,Imayama S.⁶,Kato M.¹,Hasebe I.¹,Taira K.⁶,Yamamoto M.⁷,Mihara R.⁷,Kabashima K.⁸,Ruzicka T.⁹,Hanifin J.¹⁰,Kumagai Y.¹¹

Affiliation:

1. Kojinkai, Kita13-Jo Naika-Hifuka Clinic; Hokkaido Japan

2. Department of Dermatology; Graduate School of Medical Sciences; Kyushu University; Fukuoka Japan

3. Department of Dermatology; The Jikei University School of Medicine; Tokyo Japan

4. Medical Co. LTA Hakata Clinic; Fukuoka Japan

5. Medical Co. LTA Sumida Hospital; Tokyo Japan

6. Medical Co. LTA Kyushu Clinical Pharmacology Research Clinic; Fukuoka Japan

7. Translational Clinical Research Division; Chugai Pharmaceutical Co., Ltd.; Tokyo Japan

8. Department of Dermatology; Kyoto University Graduate School of Medicine; Kyoto Japan

9. Department of Dermatology and Allergology; Ludwig-Maximilian-University Munich; Munich Germany

10. Department of Dermatology; Oregon Health and Science University; Portland OR U.S.A

11. Kitasato University School of Medicine; Kitasato Clinical Research Center; Kanagawa Japan

Funder

Chugai Pharmaceutical Co., Ltd.

Publisher

Wiley

Subject

Dermatology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjd.14207/fullpdf

Reference30 articles.

1. New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity;Kabashima;J Dermatol Sci,2013

2. Atopic dermatitis;Bieber;N Engl J Med,2008

3. What causes itch in atopic dermatitis?;Yosipovitch;Curr Allergy Asthma Rep,2008

4. Guidelines of care for the management of atopic dermatitis. Section 2. Management and treatment of atopic dermatitis with topical therapies;Eichenfield;J Am Acad Dermatol,2014

5. Guidelines of care for the management of atopic dermatitis. Section 3. Management and treatment with phototherapy and systemic agents;Sidbury;J Am Acad Dermatol,2014

Cited by 170 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Divergent sensory pathways of sneezing and coughing;Cell;2024-09

2. Current and Emerging Biologics for Atopic Dermatitis;Immunology and Allergy Clinics of North America;2024-09

3. The role of nemolizumab in the treatment of atopic dermatitis for the adult population;Immunotherapy;2024-08-09

4. Nemolizumab with concomitant topical therapy in adolescents and adults with moderate-to-severe atopic dermatitis (ARCADIA 1 and ARCADIA 2): results from two replicate, double-blind, randomised controlled phase 3 trials;The Lancet;2024-08

5. A Comprehensive Review of Biologics in Phase III and IV Clinical Trials for Atopic Dermatitis;Journal of Clinical Medicine;2024-07-09